A Phase 2 Study of HX301 in Patients with High-grade Giloma

NCT06703255 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioma

Interventions

DRUG: HX301+/Temozolomide

Sponsor

Hangzhou Hanx Biopharmaceuticals, Ltd.